Logo image of ALVAL.PA

VALBIOTIS SAS (ALVAL.PA) Stock Price, Quote, News and Overview

EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR

1.1622  +0.04 (+3.21%)

ALVAL.PA Quote, Performance and Key Statistics

VALBIOTIS SAS

EPA:ALVAL (5/8/2025, 7:00:00 PM)

1.1622

+0.04 (+3.21%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.59
52 Week Low0.94
Market Cap18.49M
Shares15.91M
Float15.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)10-27 2025-10-27
IPO06-07 2017-06-07


ALVAL.PA short term performance overview.The bars show the price performance of ALVAL.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

ALVAL.PA long term performance overview.The bars show the price performance of ALVAL.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALVAL.PA is 1.1622 EUR. In the past month the price increased by 14.12%. In the past year, price decreased by -74.68%.

VALBIOTIS SAS / ALVAL Daily stock chart

ALVAL.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1ABBV.MI ABBVIE INC 18.28 294.00B
4AB.DE ABBVIE INC 18.06 290.47B
AMG.DE AMGEN INC 13.13 129.73B
1GILD.MI GILEAD SCIENCES INC 12.71 108.39B
GIS.DE GILEAD SCIENCES INC 12.69 108.25B
VX1.DE VERTEX PHARMACEUTICALS INC 1471.92 98.38B
ARGX.BR ARGENX SE 107.09 30.99B
22UA.DE BIONTECH SE-ADR N/A 20.33B
IDP.DE BIOGEN INC 7.5 15.39B
0QF.DE MODERNA INC N/A 8.48B
1MRNA.MI MODERNA INC N/A 8.14B
BIO.DE BIOTEST AG 65.54 1.69B

About ALVAL.PA

Company Profile

ALVAL logo image Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

Company Info

VALBIOTIS SAS

12F rue Paul Vatine

Perigny NOUVELLE-AQUITAINE FR

Employees: 44

ALVAL Company Website

ALVAL Investor Relations

VALBIOTIS SAS / ALVAL.PA FAQ

What is the stock price of VALBIOTIS SAS today?

The current stock price of ALVAL.PA is 1.1622 EUR. The price increased by 3.21% in the last trading session.


What is the ticker symbol for VALBIOTIS SAS stock?

The exchange symbol of VALBIOTIS SAS is ALVAL and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALVAL.PA stock listed?

ALVAL.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for VALBIOTIS SAS stock?

11 analysts have analysed ALVAL.PA and the average price target is 3.67 EUR. This implies a price increase of 215.95% is expected in the next year compared to the current price of 1.1622. Check the VALBIOTIS SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VALBIOTIS SAS worth?

VALBIOTIS SAS (ALVAL.PA) has a market capitalization of 18.49M EUR. This makes ALVAL.PA a Nano Cap stock.


How many employees does VALBIOTIS SAS have?

VALBIOTIS SAS (ALVAL.PA) currently has 44 employees.


What are the support and resistance levels for VALBIOTIS SAS (ALVAL.PA) stock?

VALBIOTIS SAS (ALVAL.PA) has a support level at 0.99 and a resistance level at 1.38. Check the full technical report for a detailed analysis of ALVAL.PA support and resistance levels.


Is VALBIOTIS SAS (ALVAL.PA) expected to grow?

The Revenue of VALBIOTIS SAS (ALVAL.PA) is expected to decline by -96.57% in the next year. Check the estimates tab for more information on the ALVAL.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VALBIOTIS SAS (ALVAL.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VALBIOTIS SAS (ALVAL.PA) stock pay dividends?

ALVAL.PA does not pay a dividend.


When does VALBIOTIS SAS (ALVAL.PA) report earnings?

VALBIOTIS SAS (ALVAL.PA) will report earnings on 2025-10-27.


What is the Price/Earnings (PE) ratio of VALBIOTIS SAS (ALVAL.PA)?

VALBIOTIS SAS (ALVAL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.66).


ALVAL.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALVAL.PA. When comparing the yearly performance of all stocks, ALVAL.PA is a bad performer in the overall market: 97.24% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALVAL.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALVAL.PA. The financial health of ALVAL.PA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALVAL.PA Financial Highlights

Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 22.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -34.58%
ROE -53.12%
Debt/Equity 0.24
Chartmill High Growth Momentum
EPS Q2Q%-38.62%
Sales Q2Q%-99.17%
EPS 1Y (TTM)22.69%
Revenue 1Y (TTM)-88%

ALVAL.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ALVAL.PA. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of -4.38% and a revenue growth -96.57% for ALVAL.PA


Ownership
Inst Owners2.75%
Ins Owners3.99%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.45
Price Target3.67 (215.78%)
EPS Next Y-4.38%
Revenue Next Year-96.57%